FDA accepts NDA for Oxnimbi with PDUFA date of Feb 28, 2027
Apnimed reported second quarter 2026 financial results and is advancing commercial readiness for Oxnimbi following FDA acceptance of the NDA and completion of a successful IPO.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day